The document discusses the implications and risks associated with the use of generic anti-epileptic drugs (AEDs), particularly focusing on 'breakthrough seizures' experienced by patients switched from brand-name medications to generics like Mylan's Keppra. It highlights concerns raised by medical professionals regarding the safety and efficacy of these generics, citing studies that link them to increased seizure incidents and adverse side effects. Additionally, the document emphasizes the importance of patient awareness and medical consultation when transitioning between brand-name and generic AEDs.